Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORQUEST FE vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Terminal half-life: 6-8 hours. Clinical context: Supports once-daily dosing with sustained therapeutic effect.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol is metabolized via CYP3A4, with phase II conjugation (glucuronidation and sulfation). Norethindrone is metabolized via reduction and conjugation, primarily as sulfate and glucuronide conjugates.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal: 80% (50% unchanged, 30% as metabolites); Fecal: 19%; Biliary: <1%
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
97% bound to albumin and α1-acid glycoprotein.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Vd: 3.5 L/kg (~245 L for 70 kg adult). Indicates extensive tissue distribution.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: 92% (range 88-96%)
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in severe renal impairment (GFR <30 m L/min) due to lack of data.
No data available for fictional drug ALYACEN 777.
Contraindicated in patients with hepatic impairment (Child-Pugh Class B or C). No specific dose adjustment for mild impairment; use with caution.
No data available for fictional drug ALYACEN 777.
Safety and efficacy not established in postmenarchal patients; dosing follows adult regimen if indicated.
No data available for fictional drug ALYACEN 777.
Not indicated for use in postmenopausal women; no specific dose adjustment recommended due to lack of data.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. Women over 35 years old who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thromboembolic disorders, cardiovascular disease (especially in smokers over 35), hepatic neoplasia, gallbladder disease, hypertension, and glucose intolerance. Use with caution in women with risk factors for these conditions.
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
History of thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected pregnancy, carcinoma of the breast, estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, jaundice with prior OCs, liver adenoma or carcinoma, hepatic impairment, and hypersensitivity to any component.
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
Avoid calcium-rich foods (milk, yogurt, cheese) within 2 hours of dose. Vitamin C (citrus fruits, tomatoes) enhances iron absorption. Coffee, tea, and red wine reduce iron absorption; avoid within 1 hour of dosing.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: estrogen exposure associated with congenital anomalies including cardiovascular and neural tube defects. Second/third trimesters: linked to vaginal adenosis and cervical dysplasia in female offspring, potential for genitourinary abnormalities. Use of iron and calcium components generally safe, but hormonal components (estrogen/norethindrone) pose teratogenic risk.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Not recommended during breastfeeding. Estrogen and progestin may reduce milk production and quality. Small amounts of steroids and iron are excreted in breast milk; M/P ratio not established for combined hormonal contraceptives. No specific data for NORQUEST FE; avoid use.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Contraindicated in pregnancy; no dose adjustments recommended as drug should be discontinued. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) would necessitate dose increase if used, but use is contraindicated.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Contains norethindrone acetate and ethinyl estradiol. Use for iron deficiency anemia due to menstrual blood loss; iron absorption enhanced with vitamin C. Monitor for thromboembolic events, especially in smokers over 35. May reduce menstrual flow and improve iron stores over 3-6 months.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time with food to reduce nausea.,Iron may cause dark stools; this is harmless.,Avoid taking with dairy, calcium supplements, or antacids within 2 hours.,Report signs of blood clots: leg pain, chest pain, shortness of breath.,Continue for full course even if bleeding improves to prevent recurrence.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORQUEST FE vs ALYACEN 777, answered by our medical review team.
NORQUEST FE is a Oral Contraceptive that works by NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORQUEST FE and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORQUEST FE is: One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORQUEST FE and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORQUEST FE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: estrogen exposure associated with congenital anomalies including cardiovascular and n. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.